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Fibulin-4: A Novel Gene for an Autosomal Recessive Cutis Laxa Syndrome
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Cutis laxa is a condition characterized by redundant, pendulous, and inelastic skin. We identiﬁed a patient with
recessive inheritance of a missense mutation (169GrA; E57K) in the Fibulin-4 gene. She had multiple bone fractures
at birth and was diagnosed with cutis laxa, vascular tortuosity, ascending aortic aneurysm, developmental emphy-
sema, inguinal and diaphragmatic hernia, joint laxity, and pectus excavatum by age 2 years. Her skin showed
markedly underdeveloped elastic ﬁbers, and the extracellular matrix laid down by her skin ﬁbroblasts contained
dramatically reduced amounts of ﬁbulin-4. We conclude that ﬁbulin-4 is necessary for elastic ﬁber formation and
connective tissue development.
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Cutis laxa is an acquired or inherited skin disease char-
acterized by pendulous, redundant, and inelastic skin.
Inherited forms of this disease show considerable locus
heterogeneity. The cutis laxa genes discovered to date
are all important for elastic ﬁber formation. X-linked
cutis laxa, or occipital horn syndrome (OHS [MIM
304150]), is caused by mutations in the ATP7A Cu2
transporter.1 Cu2 is an essential cofactor of lysyl oxi-
dases, a family of enzymes necessary for cross-linking
ﬁbrillar collagens and elastin. Autosomal dominant cutis
laxa (ADCL [MIM 123700]) is caused by mutations in
the elastin gene,2–6 which encodes the main structural
component of elastic ﬁbers. Finally, a severe autosomal
recessive form of cutis laxa (ARCL [MIM 219100]) has
been shown to be caused by a ﬁbulin-5 mutation.7
Fibulins are a recently recognized family of extracel-
lular matrix proteins with six known members. These
molecules contain series of calcium-binding epidermal
growth factor (cbEGF) modules and a C-terminal ﬁbulin
domain.8 Fibulins interact with a multitude of extracel-
lular matrix proteins, including components of basement
membranes and elastic ﬁbers.9 Previous studies have
demonstrated that Fibulin-5 gene mutations cause cutis
laxa7 and have found reduced expression of ﬁbulin-2 in
patients with cutis laxa.10 Therefore, we hypothesized
that mutations in other members of the ﬁbulin gene fam-
ily may cause cutis laxa as well and began a systematic
mutational evaluation of ﬁbulins. We report here a ﬁ-
bulin-4 mutation associated with a new recessive cutis
laxa syndrome characterized by severe systemic connec-
tive-tissue abnormalities.
The patient, parents, and control individuals partici-
pated in this study after giving informed consent. This
study was approved by the Human Studies Committee
of Washington University School of Medicine. Tissue
samples were collected via skin biopsies. Normal control
tissue samples were provided by the CooperativeHuman
Tissue Network, which is funded by theNational Cancer
Institute. Other investigators may have received speci-
mens from the same subjects. Control DNA was ob-
tained from healthy volunteers of diverse ethnic back-
grounds. DNA was isolated from peripheral blood or
dermal ﬁbroblasts by isolation of nuclei, followed by
proteinase K digestion and phenol extraction.11
Each exon of the Fibulin-4 gene (FBLN4) was am-
pliﬁed with 80–100 bp of ﬂanking intronic sequences
(table 1) in GeneAmp 9700 PCRmachines (Applied Bio-
systems). Amplimers were subjected to direct sequence
analysis on both strands by use of the BigDye terminator
cycle sequencing chemistry (Applied Biosystems). A con-
trol DNA panel was screened for variants identiﬁed in
the proband, by use of denaturing high-performance liq-
uid chromatography.
For RNA and protein analyses, ﬁbroblasts were cul-
tured to conﬂuency at passages 4–10 in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal
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Figure 1 Generalized cutis laxa and vascular tortuosity in the
proband. Clinical photographs of the patient show sagging cheeks and
tracheal tube (A), redundant skin in the extremities (B and C), and
tortuous vessels in the periorbital area (arrows in D). In panel E,
arrows point to a tortuous vein in the right upper chest area.
Table 1
Oligonucleotides for the Ampliﬁcation of FBLN4 Exons
EXON
PRIMER
(5′r3′)
PRODUCT
SIZE
(bp)Forward Reverse
1 TACAGGGAGTTGAGGTGCCG ATTCCTGGAAGGGAACCAGAAG 111
2 TGAAGAGCCCGACAGCTACA TGAAGAGCCCGACAGCTACA 468
3 TTAGCTTGTTGAGCAGAGTGGG TTAAGACGCCTGGTGAGAGGA 396
4 TCAGTGTTGCTGGGGATGTT TGAAGCCTGGCTTGAATGG 426
5 TGGTGAAGCCTTGAGTCCCA ATGGAGAACTGTGTGGCAGG 552
6 TTCTTGACCAGCCCAGGTAGA ATGGAGAACTGTGTGGCAGGA 284
7 TTCTTCCAGTTCTGGGCAGAGA TCATCAATGTCTGTGCCAGGG 438
8 TCTGCCAAGGTACAGGTTGC ATTCCCATCATCCCTCAGGG 333
9 ATCTATTCAGACCAGCGAGTGCC TGTGCATGTCAGTTGAGGGTTG 401
10 TAGCACACAGGCTGACACAA TCAGCCACCAGGACTTTCTT 320
NOTE.—Annealing temperature was 53C for all ampliﬁcations.
bovine serum, 25 mM HEPES, L-glutamine, and anti-
biotics. Conﬂuent cultures were used to extract RNA by
use of TRI Reagent (Molecular Research Center). First-
strand cDNA was synthesized from total RNA samples
(1 mg each) by use of SuperScript III reverse transcriptase
(Invitrogen). Standard PCR reactions used AmpliTaq-
Gold polymerase (Applied Biosystems) under conditions
recommended by the manufacturer, with annealing tem-
perature of 57C. Oligonucleotide primers were designed
for exon 1 (5′-TGCTACTGTTGCTCTTGGGATCA-3′)
and exon 5 (5′-AAGGAGCCAGGCAGGTTCA-3′), to
amplify a region containing mutation E57K. A single
ampliﬁcation product was obtained from both the pa-
tient and the healthy controls, which suggests a lack of
alternative splicing or mutation-induced aberrant splic-
ing in this region of the mRNA. RT-PCR products were
subjected to DNA sequencing, to conﬁrm the presence
of the mutation at the mRNA level.
For immunoblotting, ﬁrst, the media fraction was
collected. To extract extracellular matrix, the cell layers
were washed using 10 ml of prewarmed PBS 2–3 times,
and 2 ml of 10-mM EDTA (pH 8.0) in PBS was added,
followed by shaking at room temperature for 5 min. The
EDTA extract was centrifuged at 2,000 g for 10 min.
Subsequently, cell lysates were prepared by incubating
the cell layer in 4 M urea, 1 M sodium borate, and 0.15
M NaCl for 20 min at 4C with agitation, followed by
scraping the cell layers and centrifugation. The concen-
tration of each fraction was determined by the Bradford
assay (BioRad), and a volume corresponding to 25 mg
of protein was taken. Proteins were concentrated by in-
cubating each fraction with 10 ml of StrataClean resin
(Stratagene), and the resin with bound protein was re-
suspended in 15 ml of 2# Laemmli loading buffer and
was boiled for 5 min before loading onto SDS-PAGE.
After electrophoresis, the proteins were transferred onto
polyvinylidene ﬂuoride membranes. The blots were
blocked using 5% fat-free milk in Tris-buffered saline
Tween (TBST [150 mM NaCl; 20 mM Tris-HCl, pH
7.5; and 0.1% Tween 20) and were incubated with a
monoclonal anti–ﬁbulin-4 antibody (1:100 [clone 7B9
isotype IgG2a]). The blot was washed using TBST, and
horseradish-peroxidase–conjugated secondary antibody
(1:10,000 [catalog number 674281, ICN Biomedical])
was added to the blot in fresh blocking solution. Anti-
body binding was detected using a SuperSignalWest Pico
Chemiluminescent Kit (Pierce). After ﬁbulin-4 detection,
blots were stripped and reprobed for b-actin (1:5,000
[Oncogene]). Immunoblotting experiments were re-
peated multiple times and with the use of cells cultured
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Figure 2 Skin pathology in the proband. A and B, Hematoxylin-eosin staining of samples from the patient (A) and an age- and sex-
matched control (B) revealed increased vascularization (arrowheads) and reduced collagen bundle size (arrows) in the dermis of the patient.
C and D, Hart’s elastin staining showed severely underdeveloped elastic ﬁbers in both the papillary dermis (pd) (arrowheads) and the deep
dermis (dd) (arrows) of the patient (C) compared with a matched control (D). There is no apparent pathology in the epidermis (ep).Magniﬁcation
bars p 50 mm.
under different conditions (e.g., in serum-containing
and serum-free media, with and without transforming
growth factor–b1 treatment), and similar results were
obtained. Fibulin-4 was undetectable in conditioned me-
dia of both patient and control ﬁbroblasts. Thus, media
blots are not shown.
Skin tissue in parafﬁn blocks were cut to 5-mm-thick
sections. Sections were deparafﬁnized in Histo-Clear
(National Diagnostics) and were rehydrated. All histo-
logical sections were stained with hematoxylin-eosin and
Hart’s elastic stain. For Hart’s elastin stain, sectionswere
immersed in 0.25% potassium permanganate solution
for 5 min. Slides were then cleared in 5% oxalic acid
and were soaked in resorcin-fuchsin solution overnight.
After being washed in water, sections were counter-
stained with tartrazine (yellow), were dehydrated in eth-
anol, were cleared in xylene, andweremounted. Sections
were viewed under bright-ﬁeld optics by use of an Olym-
pus Bx60 microscope. Images were acquired through a
charge-coupled device camera (Carl Zesis AxioCam
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Figure 3 Recessive inheritance of E57K mutation in ﬁbulin-4. A, DNA sequence analysis of FBLN4 revealed a homozygous 169GrA
(E57K) mutation in the patient. Both parents were heterozygous, and a healthy control individual showed wild-type sequence (Wt). B, Multiple
alignment of the peptide sequences of ﬁbulins and ﬁbrillin-1 shows the conservation of the E57 residue in all cbEGF-like modules. C, Three-
dimensional structure of a pair of cbEGF modules, based on nuclear magnetic resonance studies of ﬁbrillin-1 peptides,12 shows that the residue
corresponding to E57 is part of the calcium-binding site.
HR), were digitized via the Carl Zesis AxioVision 3.1
Image Processing System, and were archived in a desktop
personal computer.
The patient was born to unaffected parents who in-
dicated they were nonconsanguineous and had no his-
tory of cutis laxa in their respective families. Both par-
ents were of Iraqi descent. The patient was born with
multiple fractures at gestational age 36 wk, after an un-
eventful pregnancy, although oligohydramnios was re-
ported. An examination at age 9 mo revealed generalized
cutis laxa with soft, velvety, and transparent skin. Ad-
ditional observations included hypotonia, emphysema,
generalized arterial tortuosity, inguinal and diaphrag-
matic hernia, joint laxity, and pectus excavatum. At age
10 mo, she underwent diaphragmatic plication. Surgical
observations included both arterial and venous tortu-
osity, emphysematous and hyperexpanded lungs, and an
esophagus not ﬁxed to the posterior chest. The dia-
phragm contained very little muscle and mainly con-
sisted of a pleuroperitoneal membrane. Subsequent
breathing difﬁculties required the placement of a tracheal
tube (ﬁg. 1A), and, at age 2 years, she received a diag-
nosis of an aortic root aneurysm. Clinical photographs
taken at age 2 years conﬁrmed generalized cutis laxa
(ﬁg. 1A–1C) and vascular tortuosity (ﬁg. 1D and 1E).
Histological evaluation of a skin biopsy specimen taken
at the same time revealed smaller-than-normal collagen
bundles (ﬁg. 2A and 2B), increased vascularization of
the upper dermis, and severely underdeveloped elastic
ﬁbers compared with specimens from age-matched
healthy controls (ﬁg. 2C and 2D).
Screening of FBLN4 revealed a homozygous missense
mutation (169GrA; E57K) in the patient (ﬁg. 3A). Both
of her parents were heterozygous, which suggests au-
tosomal recessive inheritance. Mutation E57K was not
found in 123 unrelated healthy controls. Multiple align-
ment showed that the E57 residue was completely con-
served in cbEGF modules (ﬁg. 3B), consistent with this
residue being essential for calcium binding (ﬁg. 3C).
To investigate the effect of this mutation on ﬁbulin-4
expression, we ﬁrst conducted RT-PCR experiments, us-
ing mRNA isolated from skin ﬁbroblasts obtained from
the patient and healthy controls. FBLN4 mRNA ex-
pression in the patient was comparable to normal ex-
pression, and sequencing of RT-PCR products conﬁrmed
the presence of the E57K mutation in the patient (data
not shown). Immunoblot analysis of ﬁbulin-4 in ﬁbro-
blasts cultured under a variety of conditions showed
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Figure 4 Deﬁcient matrix incorporation of K57 ﬁbulin-4. Im-
munoblot analysis of ﬁbulin-4 expression in ﬁbroblasts from the pa-
tient (E57K) and three healthy controls (Wt 1–Wt 3). Cell lysates (Cell)
show approximately equal expression of ﬁbulin-4 in the patient and
controls. However, EDTA extract of the extracellular matrix (ECM)
shows no ﬁbulin-4 in the patient sample.
normal abundance of ﬁbulin-4 in patient cell lysates, but
extracellular matrix extracts for patient ﬁbroblast cul-
tures showed severely reduced ﬁbulin-4 content (ﬁg. 4).
Our results demonstrate for the ﬁrst time, to our
knowledge, that homozygous mutations in FBLN4
cause a severe, recessive connective-tissue disease in-
cluding cutis laxa, bone fragility, vascular tortuosity and
aneurysm, developmental emphysema, and diaphrag-
matic and inguinal hernia. Evidence that the mutation
E57K is disease causing includes conservation of this
residue in cbEGF-like domains, where it is part of the
calcium-binding consensus sequence. Lack of this mu-
tation in 123 healthy controls provides further sup-
porting evidence. Moreover, mutant ﬁbroblasts con-
tained an undetectable amount of ﬁbulin-4, showing that
mutation E57K impairs the secretion, matrix binding,
or stability of this protein. Additional evidence sup-
porting our conclusion is provided by the observation
that the same substitution at a homologous residue in
ﬁbrillin-1 (E1073K) causes severe, neonatal Marfan
syndrome.13,14
Reduced amount of elastic ﬁbers in the skin and the
clinical observations of cutis laxa, emphysema, and aor-
tic aneurysm in our patient implicate ﬁbulin-4 in elastic
ﬁber formation. Similar clinical and pathologic obser-
vations were made in autosomal dominant cutis laxa
caused by elastin gene mutations.5,6 A recent report of
targeted inactivation of ﬁbulin-4 in mice uncovered a
neonatal lethal phenotype very similar to our observa-
tions in a human: defective elastic ﬁber formation, vas-
cular tortuosity, aneurysms, rupture, and developmental
emphysema.15 Thus, the role of ﬁbulin-4 in elastic ﬁber
formation is evolutionarily conserved in mammals.
However, additional observations in our study, such as
vascular tortuosity and bone fragility, indicate that ﬁ-
bulin-4 may have additional, pleiotropic functions in
vascular patterning and collagen biosynthesis. Indeed,
the recent discovery of ﬁbulin-4 expression in chondro-
cytes supports the notion that this protein is important
for skeletal function.16
Interestingly, a missense mutation in the Fibulin-5
gene was also reported to cause recessive cutis laxa and
severe lung disease associated with abnormal elastic ﬁber
formation.7 Of note, systemic complications of ﬁbulin-
5 mutations included supravalvular aortic stenosis and
obstructive vascular disease, and no collagen-related ab-
normalities were observed.7 Studies of animals with tar-
geted disruption of the ﬁbulin-5 gene conﬁrmed the im-
portance of ﬁbulin-5 in elastic ﬁber formation17,18 and
demonstrated the ability of ﬁbulin-5 to bind both cell
surface receptors and tropoelastin. These studies, to-
gether with the present report, suggest that both ﬁbulin-
4 and ﬁbulin-5 play essential, nonoverlapping roles in
elastogenesis.
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